Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23252277 | 0.88 | CCR6 (0.38) | L3MBTL1MEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL20850496 | 0.86 | SCN1A (0.38) | MEN1KMT2ASCN1ASCN2ASCN3A | |
| SCHEMBL20254372 | 0.84 | NFE2L2 (0.36) | L3MBTL1MEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8408204 | 0.80 | ACHE (0.52) | CYP3A4ESR1ESR2TAAR1MAPT | |
| SCHEMBL19700476 | 0.80 | ESR1 (0.43) | MEN1CYP3A4KMT2AESR1ESR2 | |
| SCHEMBL19923360 | 0.80 | POLB (0.39) | LPAR1ACHENPC1LMNARAB9A | |
| SCHEMBL23344383 | 0.79 | MAPT (0.40) | L3MBTL1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10267465 | 0.77 | NR1I2 (0.41) | MEN1KMT2AHTTSMN1; SMN2CA1 | |
| SCHEMBL682768 | 0.75 | CA12 (0.58) | L3MBTL1MEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15801259 | 0.74 | GAA (0.39) | L3MBTL1CYP3A4SCN1ASCN2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| WO-2019178510-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | L3MBTL1 4748/4885MEN1 2318/4885CYP1A2 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.